AI Terminal
Photocure ASA
Transaction in Own Shares • Sep 1, 2021
3714_rns_2021-09-01_bd15d52a-be02-46ce-b51a-4212b1377117.pdf
Transaction in Own Shares
Open in ViewerOpens in native device viewer
Photocure ASA: Update on holding of own shares
Oslo, Norway, 1 September 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 31 August 2021 regarding exercise of share options and sale of own shares, together with primary insider notifications.
The sale of 7,126 option shares has been completed as previously announced. Following the transaction Photocure will hold 13,884 own shares.
For further information, please contact: Photocure CFO Erik Dahl Tel: +47 450 55 000 Email: [email protected]
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
This information is subject to the disclosure requirements set out in section 5-12 of the Norwegian Securities Trading Act.